Existing investors Legend Capital, Lilly Asia Ventures and Taikang Insurance all took part as the drug developer took its total funding to more than $530m.
China-based biopharmaceutical company Innovent Biologics closed a $150m series E round yesterday featuring insurance provider Taikang Insurance and Legend Capital, the venture capital firm formed by conglomerate Legend Holdings.
Lilly Asia Ventures, a corporate venturing subsidiary of pharmaceutical firm Eli Lilly, also participated in the round, which was led by private equity fund manager Capital Group Private Markets (CGPM) with a $90m commitment.
The round was filled out by Singaporean state-owned investment firm Temasek, Hillhouse Capital, Cormorant Asset Management, Rock…
